Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
-0.84 (-0.89%)

BRIEF-FDA Approves Merck's KEYTRUDA For Advanced MSI-H/dMMR Endometrial Cancer

Published: 03/21/2022 21:11 GMT
Merck & Co Inc (MRK) - March 21 (reuters) - Merck & Co Inc :.
FDA Approves Merck’s Keytruda® (pembrolizumab) for Patients With Msi‑h/dmmr Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery Or Radiation.